

ADVANCES IN

Cancer

IMMUNOTHERAPY™

Immunotherapy for the Treatment of Head and Neck Cancer

Laura Chow MD, FRCPC

Professor, Department of Medicine, Division of Oncology, University of Washington Associate Member, Fred Hutchinson Cancer Research Center







Society for Immunotherapy of Cancer



Disclosures

- I have served on advisory boards for Dynavax, Merck, Takeda, and Genentech.
- These relationships will not impact my ability to present an unbiased presentation.
- I will not be discussing non-FDA approved indications during my presentation.








Immunotherapy for the Treatment of Head and Neck Cancers

- Immuno-Oncology (I-O) developments in treatment of head and neck cancers
 - Expression of immunologic markers to guide treatment
 - Preventive vaccination against virally mediated cancers
 - PD-1 checkpoint inhibitors for the treatment of metastatic disease




Society for Immunotherapy of Cancer


Schoenfeld JD, Cancer Immunol Res, 2015



Immunotherapy for the Treatment of Head and Neck Cancers

Immune Checkpoint Inhibitors (ICI)





PD-1 acts as "off-switch" for T cells, allowing cancer cells to evade immune attack

Antibodies against PD-1 and PD-L1 boost the immune response against cancer cells







FDA-approved Checkpoint Inhibitors for Use in Head and Neck Cancers


- Pembrolizumab 200 mg IV Q3W (anti-PD-1)
 - KEYNOTE 012/055: Patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (HNSCC) with disease progression on or after platinum-containing chemotherapy
 - Accelerated Approval by FDA August 5, 2016
- Nivolumab 240 mg IV Q2W or 480 mg IV Q4W (anti-PD-1)
 - CheckMate 141: Patients with R/M HNSCC with disease progression on or after a platinum-based therapy
 - Breakthrough Therapy Designation by FDA April, 2016
 - Approval November 10, 2016







KEYNOTE-012: Pembrolizumab in R/M HNSCC Nonrandomized, Phase 1b Trial, Cohorts⁺ B, B2



Response assessment: Every 8 weeks until disease progression

Primary end points: ORR (RECIST v1.1, central imaging vendor review), safety

Secondary end points: ORR (investigator), PFS, OS, duration of response (DOR), ORR in HPV+ patients[§]

[†]Additional cohorts included bladder cancer, TN breast cancer, and gastric cancer.

[‡]Treatment beyond progression was allowed.

§ Initial cohort only.

*Median duration of disease not reached.


Chow, L et al. JCO November 2016







KEYNOTE-012: Pembrolizumab in R/M HNSCC Nonrandomized, Phase 1b Trial, Cohorts⁺ B, B2



- ORR = 18%
 - CR = 4%
 - PR = 14%
- mOS = 8.0 months
- mPFS = 2.2 months







KEYNOTE-012 Phase Ib Trial HNSCC Cohorts Overall Response by PD-L1 Status

	PD-L1 Status	Non- responders n	Responders n	ORR % (95% CI)	P-value
TPS (tumor	PD-L1+	101	22	18 (12–26)	0.461
cells)	PD-L1–	53	12	19 (10–30)	0.401
CPS (tumor and	PD-L1+	120	32	21 (15–28)	0.023
inflammatory cells)	PD-L1–	34	2	6 (1–19)	0.023

Incorporation of inflammatory cells improves ability to detect responders










KEYNOTE-012 Phase Ib Trial HNSCC Cohorts Overall Response by IFN-γ 6-gene Signature Score



- Score significantly associated with response⁺
- No difference in score by HPV status[‡]

P-values based on logistic regression one-sided testing.

[†]n = 150

[‡] HPV status was assessed at the local institution by p16 immunohistochemistry; n = 93.

Chow, LQ et al, oral presentation, ASCO 2016










KEYNOTE-012 Phase Ib Trial HNSCC Cohorts PD-L1, PD-L2, and IFN-γ 6-gene Signature ROC Curves for Overall Response






Association of Community Cancer Center



KEYNOTE-055: Pembrolizumab in R/M HNSCC after Progression on Platinum/Cetuximab Phase II Trial, Single Arm



 Response assessment: Imaging every 6 to 9 weeks (central radiology review)
 BaumI J JCO 2017

 Primary end points: ORR (RECIST v1.1) by Response Evaluation Criteria in Solid Tumors and safety
 Secondary end points: ORR (RECIST v1.1) in all dosed patients, ORR for HPV+, PD-L1+, DOR, PFS, OS

 *75% of patients had ≥ 2 prior lines of therapy for metastatic disease
 *75%





KEYNOTE-055: Pembrolizumab in R/M HNSCC after Progression on Platinum/Cetuximab Phase II Trial, Single Arm

	All Patients	HPV Status		PD-L1 Status		JS
Outcome	N=171	Positive n=37	Negative n=131	≥1% n=140	<1% n=26	≥50% n=48
ORR, %	16	16	15	18	12	27
mPFS, mo	2.1					
6-mo PFS,%	23	25	21	24	20	31
6-mo OS, %	59	72	55	59	56	60

Neither tumor PD-L1 expression or HPV status are sufficiently robust in guiding the use of pembrolizumab at this time.






© 2018–2019 Society for Immunotherapy of Cancer

Bauml J, et al, J Clin Oncol. 2017



Combined biomarker data from Keynote 012 and Keynote 055 Studies

- First reported biomarker relationships in head and neck cancer:
 - AUROC curves for the relationship of PDL1 immunohistochemistry combined proportional score (IHC CPS), Gene expression profiling (GEP) and tumor mutational burden (TMB)



Siewert T et al. and Chow LQM. AACR 2018







CheckMate 141: Nivolumab vs Investigator's Choice in R/M HNSCC after Platinum Therapy Phase III Randomized, Safety and Efficacy Trial


Key Eligibility Criteria

- R/M SCCHN of the oral cavity, pharynx, or larynx
- Progression on or within 6 months of last dose of platinum-based therapy
- Irrespective of no. of prior lines of therapy
- Documentation of p16 to determine HPV status (oropharyngeal)
- Regardless of PD-L1 status^a

Stratification factor

• Prior cetuximab treatment

^aTissue required for testing



DOR = duration of response; IV = intravenous; ORR = objective response rate; PFS = progression-free survival; Q2W = once every 2 weeks; R = randomized. Clinicaltrials.gov NCT02105636.

Ferris & Gillison, NEJM, 2016










Checkmate 141: Nivolumab vs Investigator's Choice in R/M HNSCC after Platinum Therapy Overall Survival: 2 year report



Ferris RL. Oral Oncology, 2018










Response to Immune Checkpoint Inhibitor Treatment with Brief Increase in Tumor Size

Pseudoprogression

- Early appearance of an increase in tumor burden, subsequently followed by tumor regression
- Initially recognized in the melanoma trials, with incidence up to 10%



Ferris RL, et al. N Engl J Med. 2016 Seiwert TY, et al. Lancet Oncol. 2016









Response to Immune Checkpoint Inhibitor Treatment with Brief Increase in Tumor Size

Case Report – KEYNOTE-012



Both KEYNOTE-012

 and CheckMate 141
 trials showed an
 exceedingly rare rate
 of pseudoprogression
 with pembrolizumab
 and nivolumab,
 respectively.

Ferris RL, et al. N Engl J Med. 2016 Seiwert TY, et al. Lancet Oncol. 2016









Evaluating Biomarkers in HNSCC


- Current FDA approvals of pembrolizumab and nivolumab are NOT contingent upon tumor PD-L1 status
 - KEYNOTE 012/055: Response rates not significantly different on the basis of tumor PD-L1 staining
 - KEYNOTE 040: Phase III pembrolizumab vs. investigator's choice chemotherapy
 - Did not meet survival endpoints in total population but improved outcomes in patients with PD-L1 expressing tumor
 - CheckMate 141: Most benefit was seen in PD-L1-positive tumors





Evaluating Biomarkers in HNSCC

CheckMate 141: 2 year update









Immune-related Adverse Events

KEYNOTE 012

Table 2.	Treatment-Related Adverse Events by Grade Severity (all-patients-as	3-
	treated population; $N = 132$)	

Treatment-Related Adverse Event	Grade 1 or 2 ($\geq 10\%$ of patients),	Grade 3 (any occurrence),	Grade 4 (any occurrence),
Adverse Event	No. (%)	No. (%)	No. (%)
Patients with ≥ 1 event	70 (53)	8 (6)	4 (3)
Hypothyroidism	14 (11)	0	0
Immune thrombocytopenic purpura	0	0	1 (1)
Abdominal pain	1 (1)	1 (1)	0
Colitis	0	1 (1)	0
Dysphagia	1 (1)	1 (1)	0
Nausea	6 (5)	1 (1)	0
Stomatitis	1 (1)	1 (1)	Û
Facial edema	0	1 (1)	0
Fatigue	28 (21)	0	0
Localized edema	0	1 (1)	0
Infection	0	1 (1)	0
Decreased appetite	9 (7)	2 (2)	0
Dehydration	0	T (T)	0
Diabetic ketoacidosis	0	0	1 (1)
Hyperglycemia	1 (1)	0	1 (1)
Type I diabetes mellitus	0	1 (1)	0
Laryngeal edema	0	0	1 (1)
Pneumonitis	2 (2)	2 (2)	0
Respiratory distress	0	1 (1)	0
Facial swelling	3 (2)	1 (1)	1 (1)
_			

CheckMate 141

Event	Nivolumab (N=236)		
	Any Grade	Grade 3 or 4	
Any event	139 (58.9)*	31 (13.1)	
Fatigue	33 (14.0)	5 (2.1)	
Nausea	20 (8.5)	0	
Rash	18 (7.6)	0	
Decreased appetite	17 (7.2)	0	
Pruritus	17 (7.2)	0	
Diarrhea	16 (6.8)	0	
Anemia	12 (5.1)	3 (1.3)	
Asthenia	10 (4.2)	1 (0.4)	
Vomiting	8 (3.4)	0	
Dry skin	7 (3.0)	0	
Stomatitis	5 (2.1)	1 (0.4)	
Weight loss	4 (1.7)	0	
Mucosal inflammation	3 (1.3)	0	
Peripheral neuropathy	1 (0.4)	0	
Alopecia	0	0	
Neutropenia	0	0	









Immune-related Adverse Events

Table 2 General guidance for corticosteroid management of immune-related adverse events


Grade of immune-related AE (CTCAE/equivalent)	Corticosteroid management	Additional notes
1	Corticosteroids not usually indicated	Continue immunotherapy
2	 If indicated, start oral prednisone 0.5-1 mg/kg/day if patient can take oral medication. If IV required, start methylprednisolone 0.5-1 mg/kg/day IV If no improvement in 2–3 days, increase corticosteroid dose to 2 mg/kg/day Once improved to ≤grade 1 AE, start 4–6 week steroid taper 	 Hold immunotherapy during corticosteroid use Continue immunotherapy once resolved to ≤grade 1 and off corticosteroids Start proton pump inhibitor for GI prophylaxis
3	 Start prednisone 1-2 mg/kg/day (or equivalent dose of methylprednisolone) If no improvement in 2–3 days, add additional/alternative immune suppressant Once improved to ≤ grade 1, start 4–6-week steroid taper Provide supportive treatment as needed 	 Hold immunotherapy; if symptoms do not improve in 4–6 weeks, discontinue immunotherapy Consider intravenous corticosteroids Start proton pump inhibitor for GI prophylaxis Add PCP prophylaxis if more than 3 weeks of immunosuppression expected (>30 mg prednisone or equivalent/day)
4	 Start prednisone 1-2 mg/kg/day (or equivalent dose of methylprednisolone) If no improvement in 2–3 days, add additional/alternative immune suppressant, e.g., infliximab Provide supportive care as needed 	 Discontinue immunotherapy Continue intravenous corticosteroids Start proton pump inhibitor for GI prophylaxis Add PCP prophylaxis if more than 3 weeks of immunosuppression expected (>30 mg prednisone or equivalent/day)







Keynote-048: Phase 3 Study of First-Line Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (NCT02358031)



^aAssessed using the PD-L1 IHC 22C3 pharmDx assay (Agilent). TPS = tumor proportion score = % of tumor cells with membranous PD-L1 expression. ^bAssessed using the CINtec p16 Histology assay (Ventana); cutpoint for positivity = 70%. ^cFollowing a loading dose of 400 mg/m².


Burtness B et al. ESMO Munich 2018

Keynote-048: Phase 3 Study of First-Line Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (NCT02358031 Burtness B et al. ESMO Munich 2018

Response Summary, P vs E


Confirmed Response, n (%)	Pembro N = 133	EXTREME N = 122
ORR	31 (23.3)	44 (36.1)
CR	10 (7.5)	4 (3.3)
PR	21 (15.8)	40 (32.8)
SD	40 (30.1)	42 (34.4)
PD	42 (31.6)	13 (10.7)
Non-CR/non-PD ^a	8 (6.0)	6 (4.9)
Not evaluable or assessed $^{\mathrm{b}}$	12 (9.0)	17 (13.9)

CPS ≥20



Confirmed Response, n (%)	Pembro N = 257	EXTREME N = 255
ORR	49 (19.1)	89 (34.9)
CR	14 (5.4)	7 (2.7)
PR	35 (13.6)	82 (32.2)
SD	72 (28.0)	83 (32.5)
PD	100 (38.9)	34 (13.3)
Non-CR/non-PD ^a	11 (4.3)	11 (4.3)
Not evaluable or assessed ^b	25 (9.7)	38 (14.9)


CPS ≥1



^aPatients without measurable disease per central review at baseline who did not have CR or PD. ^bPatients who did not have a post-baseline imaging assessment evaluable for response or who did not have post-baseline imaging. Response assessed per RECIST v1.1 by blinded, independent central radiologic review. Data cutoff date: Jun 13, 2018.


Keynote-048: Phase 3 Study of First-Line Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (NCT02358031) Burtness B et al. ESMO Munich 2018

Overall Survival: P vs E, CPS ≥20 Population



Keynote-048: Phase 3 Study of First-Line Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (NCT02358031) Burtness B et al. ESMO Munich 2018


Overall Survival: P vs E, CPS ≥1 Population



Keynote-048: Phase 3 Study of First-Line Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (NCT02358031 Burtness B et al. ESMO Munich 2018


Response Summary, P+C vs E, Total Population

Confirmed Response, n (%)	Pembro + Chemo N = 281	EXTREME N = 278
ORR	100 (35.6)	101 (36.3)
CR	17 (6.0)	8 (2.9)
PR	83 (29.5)	93 (33.5)
SD	78 (27.8)	94 (33.8)
PD	48 (17.1)	34 (12.2)
Non-CR/non-PDª	13 (4.6)	9 (3.2)
Not evaluable or assessed ^ь	42 (14.9)	40 (14.4)




Keynote-048: Phase 3 Study of First-Line Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (NCT02358(Burtness B et al. ESMO Munich 2018

Overall Survival: P+C vs E, Total Population





Developmental Immunotherapies for HNSCC



- Durvalumab, atezolizumab, avelumab, CK-301 (anti-PD-L1)
- Cemiplimab (anti-PD-1)
- Ipilimumab, tremelimumab (anti-CTLA-4)
- Varlilumab (anti-CD27)
- PF-04518600, tavolimab (anti-OX40)







Developmental Immunotherapies for HNSCC: MASTERKEY 232/KEYNOTE 137

- Talimogene laherparepvec (T-Vec)
 - Genetically engineered herpes virus
- T-Vec 10⁶ PFU/mL intratumoral injection followed by 10⁸ PFU/mL Q3W
- Pembrolizumab 200 mg IV Q3W
- Eligibility:
 - R/M HNSCC not suitable for curative therapy
 - Progressed after platinum treatment
 - At least 1 injectable cutaneous, subcutaneous, or nodal tumor ≥ 10 mm in longest diameter





59 year old female – original diagnosis stage III T2N2M0 squamous cell carcinoma of the supraglottic larynx 2012

- Treated with radiation 75Gy in 35 fractions with concurrent cisplatin completed 2/2012
- Recurrence submandibular region resected
 5/2014
- Neck recurrence treated with neck dissection, radiation 60Gy in 30 fractions with concurrent Cetuximab 8/2014
- Local parotid recurrence, treated with
 Carboplatin + Taxol, 7/2015- 11/2015 with
 subsequent progression.
- Next options?







ADVANCES IN Cancer OF Immunotherapy of Cancer IMMUNOTHERAPYTM Patient Case Study 1: July 2017

- Initial enlargement then rapid decrease and resolution with nivolumab on clinical trial x 6 months in 2016
- Subsequent progression enrolled on two immunotherapy combination trials without benefit and continued progression in late 2016 and early 2017
- 07/2017 Recurrence with increasing pain, lesion in her left neck area increased 40% with protrusion from left ear, headaches
- ECOG 1 and no signs metastatic spread
- Next steps?









- Re-treatment with chemotherapy – carboplatin and taxol weekly with complete response
- Durable to present










- 59-y/o woman with with stage IVB of the right tonsillar base of tongue, p16 negative, prior smoker
 - Treated with docetaxel, cisplatin and 5-FU x 2 cycles with partial response followed by weekly cetuximab with radiation 7000 gy over 35 fractions, with partial response followed by two subsequent cycles of paclitaxel, carboplatin and cetuximab x2 cycles completed January 2014.
 - Developed metastatic squamous cell carcinoma involving mediastinal lymph nodes and multiple lung metastases in August 2014
 - Started on pembrolizumab on Keynote 012 study August 2014 with near complete response in lymph nodes and lungs after 6 months of therapy
 - Developed localized neck recurrence with biopsy proven disease in summer 2015
 - Next steps?










- Repeat neck irradiation of 30Gy in 10 fractions complicated by mucositis and dehydration and renal insufficiency from which she recovered from.
- Continued on pembrolizumab on clinical trial until required discontinuation after 2 years of therapy
- Received first dose FDA approved pembrolizumab September 2016 with rapid progression of right neck lymph node
- Subsequently pursued two clinical trials of combination immunotherapy with continued progression
- Surgically resected/debulked disease in 2017
- Resumed pembrolizumab immunotherapy post surgery with no recurrence x 6 months










- Fall of 2017 developed slight persistent elevation of creatinine to 1.5 to 1.8 mg/dl range with disease recurrence in surgical site
- Referral to nephrology – renal biopsy shows acute interstitial nephritis
- Patient passed in January 2018





Conclusions

- 1. Chemotherapy offers short survival with many side effects
- 2. PD-1 antibodies nivolumab and pembrolizumab are approved in *platinum-refractory* recurrent / metastatic HNSCC.
- 3. Most patients have fewer side effects on PD-1 Abs than on chemotherapy
- 4. Clinical trials are underway to improve immunotherapy response rates and testing immunotherapy in other settings

